WHO drops hydroxychloroquine from coronavirus trial after studies suggest inefficacy

Listen
Text
  • Small
  • Medium
  • Large

The World Health Organization has pulled malaria drug hydroxychloroquine from its global study assessing possible treatments for COVID-19, according to a June 17 CNBC report.

The drug, which garnered national attention in March when it was touted by President Donald Trump, has been a subject of scrutiny as conflicting studies emerge on its efficacy in treating COVID-19. Small studies suggesting the drug could be a helpful treatment for the disease have been outweighed by larger studies revealing evidence that the drug was not effective and caused heart problems in some COVID-19 patients.

WHO's announcement comes two days after the FDA rescinded its emergency use authorization for hydroxychloroquine and chloroquine, citing the same reasons as WHO.

 

The World Health Organization has pulled malaria drug hydroxychloroquine from its global study assessing possible treatments for COVID-19, according to a June 17 CNBC report.

The drug, which garnered national attention in March when it was touted by President Donald Trump, has been a subject of scrutiny as conflicting studies emerge on its efficacy in treating COVID-19. Small studies suggesting the drug could be a helpful treatment for the disease have been outweighed by larger studies revealing evidence that the drug was not effective and caused heart problems in some COVID-19 patients.

WHO's announcement comes two days after the FDA rescinded its emergency use authorization for hydroxychloroquine and chloroquine, citing the same reasons as WHO.

 

 

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars